vs
C4 Therapeutics, Inc.（CCCC）与Lakeside Holding Ltd（LSH）财务数据对比。点击上方公司名可切换其他公司
C4 Therapeutics, Inc.的季度营收约是Lakeside Holding Ltd的1.6倍（$11.0M vs $7.0M），Lakeside Holding Ltd净利率更高（-22.6% vs -186.0%，领先163.4%），C4 Therapeutics, Inc.同比增速更快（112.8% vs 95.0%）
C4 Therapeutics是一家临床阶段生物制药企业，专注于开发靶向蛋白降解疗法，用于治疗癌症及其他存在重大未满足医疗需求的严重疾病。公司依托自有专利TORPEDO平台设计小分子降解剂清除致病蛋白，目前拥有多条肿瘤领域研发管线，并与头部制药企业达成战略合作。
莱克赛德出版社是位于美国芝加哥的出版品牌，由RR唐纳利公司运营。该社除了出版高品质书籍外，还承印邮购目录、电话号码簿、百科全书与广告宣传品，最为人熟知的是为芝加哥卡克斯顿俱乐部出版的高端版本，以及经典重印丛书《莱克赛德经典》。
CCCC vs LSH — 直观对比
营收规模更大
CCCC
是对方的1.6倍
$7.0M
营收增速更快
CCCC
高出17.8%
95.0%
净利率更高
LSH
高出163.4%
-186.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $11.0M | $7.0M |
| 净利润 | $-20.5M | $-1.6M |
| 毛利率 | — | 27.2% |
| 营业利润率 | -210.1% | -21.3% |
| 净利率 | -186.0% | -22.6% |
| 营收同比 | 112.8% | 95.0% |
| 净利润同比 | 40.7% | 18.7% |
| 每股收益（稀释后） | $-0.09 | $-0.08 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CCCCLSH
| Q4 25 | $11.0M | $7.0M | ||
| Q3 25 | $11.2M | $6.1M | ||
| Q2 25 | $6.5M | $6.3M | ||
| Q1 25 | $7.2M | $3.8M | ||
| Q4 24 | $5.2M | $3.6M | ||
| Q3 24 | $15.4M | $4.1M | ||
| Q2 24 | $12.0M | — | ||
| Q1 24 | $3.0M | — |
净利润CCCCLSH
| Q4 25 | $-20.5M | $-1.6M | ||
| Q3 25 | $-32.2M | $-1.4M | ||
| Q2 25 | $-26.0M | $-893.1K | ||
| Q1 25 | $-26.3M | $-1.1M | ||
| Q4 24 | $-34.6M | $-1.9M | ||
| Q3 24 | $-24.7M | $-1.3M | ||
| Q2 24 | $-17.7M | — | ||
| Q1 24 | $-28.4M | — |
毛利率CCCCLSH
| Q4 25 | — | 27.2% | ||
| Q3 25 | — | 18.2% | ||
| Q2 25 | — | 26.7% | ||
| Q1 25 | — | 18.8% | ||
| Q4 24 | — | -1.2% | ||
| Q3 24 | — | 12.8% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
营业利润率CCCCLSH
| Q4 25 | -210.1% | -21.3% | ||
| Q3 25 | -306.4% | -20.8% | ||
| Q2 25 | -441.0% | -8.9% | ||
| Q1 25 | -402.9% | -28.2% | ||
| Q4 24 | -728.4% | -55.6% | ||
| Q3 24 | -183.9% | -32.5% | ||
| Q2 24 | -178.6% | — | ||
| Q1 24 | -1060.2% | — |
净利率CCCCLSH
| Q4 25 | -186.0% | -22.6% | ||
| Q3 25 | -286.4% | -22.2% | ||
| Q2 25 | -402.6% | -14.2% | ||
| Q1 25 | -363.7% | -28.2% | ||
| Q4 24 | -667.8% | -54.1% | ||
| Q3 24 | -160.6% | -32.7% | ||
| Q2 24 | -147.6% | — | ||
| Q1 24 | -933.2% | — |
每股收益（稀释后）CCCCLSH
| Q4 25 | $-0.09 | $-0.08 | ||
| Q3 25 | $-0.44 | $-0.09 | ||
| Q2 25 | $-0.37 | $-0.11 | ||
| Q1 25 | $-0.37 | $-0.14 | ||
| Q4 24 | $-0.50 | $-0.26 | ||
| Q3 24 | $-0.35 | $-0.18 | ||
| Q2 24 | $-0.26 | — | ||
| Q1 24 | $-0.41 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $74.6M | $1.6M |
| 总债务越低越好 | — | $2.4M |
| 股东权益账面价值 | $256.6M | $12.2M |
| 总资产 | $359.1M | $24.3M |
| 负债/权益比越低杠杆越低 | — | 0.20× |
8季度趋势，按日历期对齐
现金及短期投资CCCCLSH
| Q4 25 | $74.6M | $1.6M | ||
| Q3 25 | $58.8M | $4.5M | ||
| Q2 25 | $78.2M | $5.0M | ||
| Q1 25 | $51.3M | $1.5M | ||
| Q4 24 | $55.5M | $1.1M | ||
| Q3 24 | $59.6M | $2.7M | ||
| Q2 24 | $73.1M | — | ||
| Q1 24 | $89.7M | — |
总债务CCCCLSH
| Q4 25 | — | $2.4M | ||
| Q3 25 | — | $2.4M | ||
| Q2 25 | — | $1.4M | ||
| Q1 25 | — | $774.2K | ||
| Q4 24 | — | $784.8K | ||
| Q3 24 | — | $589.9K | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益CCCCLSH
| Q4 25 | $256.6M | $12.2M | ||
| Q3 25 | $154.4M | $7.0M | ||
| Q2 25 | $174.1M | $2.8M | ||
| Q1 25 | $195.1M | $749.8K | ||
| Q4 24 | $216.0M | $1.6M | ||
| Q3 24 | $242.7M | $3.6M | ||
| Q2 24 | $247.1M | — | ||
| Q1 24 | $258.3M | — |
总资产CCCCLSH
| Q4 25 | $359.1M | $24.3M | ||
| Q3 25 | $265.5M | $18.6M | ||
| Q2 25 | $296.5M | $14.4M | ||
| Q1 25 | $319.5M | $9.9M | ||
| Q4 24 | $349.6M | $9.8M | ||
| Q3 24 | $376.1M | $10.8M | ||
| Q2 24 | $381.1M | — | ||
| Q1 24 | $398.4M | — |
负债/权益比CCCCLSH
| Q4 25 | — | 0.20× | ||
| Q3 25 | — | 0.35× | ||
| Q2 25 | — | 0.48× | ||
| Q1 25 | — | 1.03× | ||
| Q4 24 | — | 0.48× | ||
| Q3 24 | — | 0.16× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-22.1M | $-453.5K |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流CCCCLSH
| Q4 25 | $-22.1M | $-453.5K | ||
| Q3 25 | $-31.2M | $-4.0M | ||
| Q2 25 | $-12.1M | $-483.7K | ||
| Q1 25 | $-33.3M | $-238.3K | ||
| Q4 24 | $-17.9M | $-530.2K | ||
| Q3 24 | $-24.1M | $-1.4M | ||
| Q2 24 | $-5.0M | — | ||
| Q1 24 | $-18.1M | — |
自由现金流CCCCLSH
| Q4 25 | — | — | ||
| Q3 25 | $-31.6M | — | ||
| Q2 25 | — | $-497.4K | ||
| Q1 25 | — | — | ||
| Q4 24 | $-17.9M | $-560.5K | ||
| Q3 24 | $-24.1M | $-1.4M | ||
| Q2 24 | $-5.2M | — | ||
| Q1 24 | — | — |
自由现金流率CCCCLSH
| Q4 25 | — | — | ||
| Q3 25 | -281.5% | — | ||
| Q2 25 | — | -7.9% | ||
| Q1 25 | — | — | ||
| Q4 24 | -346.5% | -15.6% | ||
| Q3 24 | -157.2% | -34.5% | ||
| Q2 24 | -43.1% | — | ||
| Q1 24 | — | — |
资本支出强度CCCCLSH
| Q4 25 | — | — | ||
| Q3 25 | 3.7% | — | ||
| Q2 25 | — | 0.2% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | 0.1% | 0.8% | ||
| Q3 24 | 0.1% | 0.1% | ||
| Q2 24 | 1.6% | — | ||
| Q1 24 | 0.0% | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CCCC
暂无分部数据
LSH
| Transferred Over Time | $4.6M | 65% |
| Distribution Of Pharmaceutical Products | $2.4M | 35% |
